Harmony Biosciences (NASDAQ:HRMY – Get Free Report) and Phibro Animal Health (NASDAQ:PAHC – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.
Valuation and Earnings
This table compares Harmony Biosciences and Phibro Animal Health”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Harmony Biosciences | $868.45 million | 2.77 | $158.69 million | $3.08 | 13.40 |
| Phibro Animal Health | $1.52 billion | 0.92 | $99.72 million | $2.44 | 14.12 |
Volatility & Risk
Harmony Biosciences has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Harmony Biosciences and Phibro Animal Health, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Harmony Biosciences | 1 | 5 | 5 | 0 | 2.36 |
| Phibro Animal Health | 0 | 2 | 1 | 1 | 2.75 |
Harmony Biosciences currently has a consensus target price of $47.11, suggesting a potential upside of 14.18%. Phibro Animal Health has a consensus target price of $47.67, suggesting a potential upside of 38.36%. Given Phibro Animal Health’s stronger consensus rating and higher probable upside, analysts plainly believe Phibro Animal Health is more favorable than Harmony Biosciences.
Insider and Institutional Ownership
86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Harmony Biosciences and Phibro Animal Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Harmony Biosciences | 18.88% | 20.06% | 14.15% |
| Phibro Animal Health | 6.57% | 37.86% | 9.18% |
Summary
Phibro Animal Health beats Harmony Biosciences on 8 of the 15 factors compared between the two stocks.
About Harmony Biosciences
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
About Phibro Animal Health
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock’s diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
